Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Trial details
- Registry ID
- NCT03459287
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery PatientsNCT03459287 | Cerus Corporation | Phase 3 | Completed | 2023-12-04Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |